Drugs / tissue-type plasminogen activator
tissue-type plasminogen activator
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00000472 | Apr 1989 → Jun 1995 | coronary artery disorder, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tissue-type plasminogen activator | “The Thrombolysis in Myocardial Ischemia (TIMI) 3B trial compared recombinant tissue-type plasminogen activator (rt-PA) (35-80 mg) with placebo and early catheterisation with...” PMID 33262195 ↗ Dec 2020 |
| Known as | rt-PA | “The Thrombolysis in Myocardial Ischemia (TIMI) 3B trial compared recombinant tissue-type plasminogen activator (rt-PA) (35-80 mg) with placebo and early catheterisation with...” PMID 33262195 ↗ Dec 2020 |
| Known as | t-PA | “The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary...” NCT00000472 ↗ |
| Modality | Protein / enzyme biologic | “The Thrombolysis in Myocardial Ischemia (TIMI) 3B trial compared recombinant tissue-type plasminogen activator (rt-PA) (35-80 mg) with placebo and early catheterisation with...” PMID 33262195 ↗ Dec 2020 |